| __timestamp | Amphastar Pharmaceuticals, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 13774000 |
| Thursday, January 1, 2015 | 46974000 | 22479000 |
| Friday, January 1, 2016 | 47298000 | 27388000 |
| Sunday, January 1, 2017 | 50918000 | 35610000 |
| Monday, January 1, 2018 | 58044000 | 49007000 |
| Tuesday, January 1, 2019 | 63109000 | 61139000 |
| Wednesday, January 1, 2020 | 65157000 | 68836000 |
| Friday, January 1, 2021 | 68920000 | 97592000 |
| Saturday, January 1, 2022 | 66592000 | 106903000 |
| Sunday, January 1, 2023 | 80393000 | 120998000 |
In pursuit of knowledge
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Vericel Corporation and Amphastar Pharmaceuticals, Inc. over the past decade.
From 2014 to 2023, Vericel Corporation's SG&A expenses surged by approximately 780%, reflecting its aggressive growth strategy and increased market presence. In contrast, Amphastar Pharmaceuticals, Inc. experienced a more modest increase of around 99%, indicating a steady yet cautious expansion approach.
By 2023, Vericel's SG&A expenses reached a peak, surpassing Amphastar's by nearly 50%. This trend highlights Vericel's commitment to scaling its operations and enhancing its competitive edge. Investors and industry analysts should consider these financial dynamics when evaluating the strategic directions of these two companies.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Breaking Down SG&A Expenses: argenx SE vs Vericel Corporation
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Dr. Reddy's Laboratories Limited and Vericel Corporation: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Vericel Corporation vs Wave Life Sciences Ltd. Trends and Insights
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.